Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. 2021

Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), University of Valladolid (UVa)-CSIC, 47003 Valladolid, Spain.

Colorectal cancer (CRC) is a global public health problem as it is the third most prevalent and the second most lethal cancer worldwide. Major efforts are underway to understand its molecular pathways as well as to define the tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs) or neoantigens, in order to develop an effective treatment. Cell therapies are currently gaining importance, and more specifically chimeric antigen receptor (CAR)-T cell therapy, in which genetically modified T cells are redirected against the tumour antigen of interest. This immunotherapy has emerged as one of the most promising advances in cancer treatment, having successfully demonstrated its efficacy in haematological malignancies. However, in solid tumours, such as colon cancer, it is proving difficult to achieve the same results due to the shortage of TSAs, on-target off-tumour effects, low CAR-T cell infiltration and the immunosuppressive microenvironment. To address these challenges in CRC, new approaches are proposed, including combined therapies, the regional administration of CAR-T cells and more complex CAR structures, among others. This review comprehensively summarises the current landscape of CAR-T cell therapy in CRC from the potential tumour targets to the preclinical studies and clinical trials, as well as the limitations and future perspectives of this novel antitumour strategy.

UI MeSH Term Description Entries
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000076962 Receptors, Chimeric Antigen Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens. Chimeric Antigen Receptor,Chimeric T-Cell Receptor,Artificial T-Cell Receptors,Chimeric Antigen Receptors,Chimeric Immunoreceptors,Chimeric T-Cell Receptors,Antigen Receptor, Chimeric,Antigen Receptors, Chimeric,Artificial T Cell Receptors,Chimeric T Cell Receptor,Chimeric T Cell Receptors,Immunoreceptors, Chimeric,Receptor, Chimeric Antigen,Receptor, Chimeric T-Cell,Receptors, Artificial T-Cell,Receptors, Chimeric T-Cell,T-Cell Receptor, Chimeric,T-Cell Receptors, Artificial,T-Cell Receptors, Chimeric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D064987 Cell- and Tissue-Based Therapy Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues. Cell Therapy,Tissue Therapy,Therapy, Cell,Therapy, Tissue,Cell and Tissue Based Therapy

Related Publications

Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
November 2019, Cellular immunology,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
November 2017, JAMA oncology,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
February 2017, Nihon rinsho. Japanese journal of clinical medicine,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
January 2020, Journal of clinical medicine,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
November 2014, Discovery medicine,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
January 2022, Cancer treatment and research,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
March 2022, Neuromolecular medicine,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
October 2016, Oncology (Williston Park, N.Y.),
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
July 2017, Cancers,
Cristina Aparicio, and Marina Belver, and Lucía Enríquez, and Francisco Espeso, and Lucía Núñez, and Ana Sánchez, and Miguel Ángel de la Fuente, and Margarita González-Vallinas
April 2023, Cancer medicine,
Copied contents to your clipboard!